The new generation of MDS diagnostics: the Myeloid Gene Panel20 Jun. 2019
Research FOR Patients
-For an informed and empowered opinion-
Have you made your clinical paper accessible yet?
What are Myeloid Gene Panels and how are they used in MDS?
Myeloid Gene Panels are a set of specific genes present in MDS patients, whose mutations are thought to be driving MDS. These genes can be identified with innovative genetic tests.
Prof Nick Cross, professor of Human Genetics at the University of Southampton says:
MDS is a very complex disorder, but, as with all these different types of disorders, they are fundamentally driven by abnormalities of genes that are acquired during the lifetime of an individual.
What we are looking for is the large number of genes that are involved in MDS to see whether there are specific mutations, changes in those genes, that may actually be driving MDS.
Finding these can increase the confidence that this is really a diagnosis of MDS. We also know that some particular genes are associated with a better or a worse prognosis, and that they may indicate specific types of treatment.
Take a look at what is being done in the Wessex region, through a number of services, including Myeloid Gene Panels, and why such tests and technologies are used to help scientists and physicians in their diagnosis of MDS.
- MS Sophie Laird, Clinical Scientist , Wessex Regional Genetic Laboratory
- Dr Sally Killick , Consultant Haematologist, Bournemouth Hospital
- Prof Nick Cross, professor of Human Genetics at the University of Southampton
The Myelod Gene Panel and how it helps MDS Patients
Dr Lynn Quek, Consultant Haematologist and Research Scientist at Oxford University Hospital, is interviewed by Sophie Wintrich.
She explains the impact that Myeloid Gene Panel data has on treatment decisions in MDS, and how the genetic information of individual patients helps to personalise and tailor their clinical care.